Abstract:A major clinical obstacle in cancer therapy is the development of resistance to chemotherapeutic agents. Intrinsic or acquired drug resistance occurs frequently in most cancers. Many strategies are being developed towards overcoming such drug resistance. Among them, application of nanotechnology has shown promise in the development of novel drug delivery approaches to overcome drug resistance by targeting tumor tissue, tumor cells, or compartments within tumor cells. We synthesized a targeted nanoparticle composed of heparin-folate-paclitaxel (HFT) conjugates and loaded with paclitaxel in its hydrophobic core (HFT-T). In vitro cytotoxicity of the HFT-T nanoparticle was assessed in a resistant human squamous cancer cell line KB-8-5 (10-fold more resistant to paclitaxel than the parental sensitive cell line KB-3-1). The targeted nanoparticle HFT-T was more effective in inhibiting cell growth when compared with the non-targeted nanoparticle (HT-T). To test the in vivo efficacy of HFT-T particles, nude mice bearing subcutaneous human KB-8-5 tumors were randomly divided into four groups (n=8 per group), and treated with HFT-T, free paclitaxel, HT-T or PBS (control). The drugs (at a dose of 40 mg/kg paclitaxel equivalent) were administrated via tail vein every four days for 3 weeks (4 injections in total). At the end of the experiment, the HFT-T-treated group showed the smallest tumor sizes (average tumor volume of 785.5±104.1 mm 3 ) when compared with other treated mice or controls (average tumor volumes in free paclitaxel, HT-T-treated, and control groups were 1422.9 ± 216.1 mm 3 , 1301.2 ± 213.9 mm 3 , 2061.7± 416.1, respectively). Compared with free paclitaxel and non-targeted nanoparticle HT-T treated groups, HFT-T treatment significantly reduced tumor size (paclitaxel vs. HFT-T p=0.0155, HT-T vs. HFT-T p=0.0381). Also, compared with the control group, only HFT-T treatment significantly reduced tumor size (p=0.0075). Furthermore, the effect of HFT-T on microtubule organization and apoptosis in tumor will be studied. In conclusion, this study provides a novel strategy using a targeted nanoparticle as a drug delivery system to minimize drug resistance in human cancers. (Supported by NCI P50 CA128613 and U54CA119338-04) Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3667.

Novel Therapeutic Potential in Targeting Microtubules by Nanoparticle Albumin-Bound Paclitaxel in Hepatocellular Carcinoma

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene

N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma

Abstract 303: Surface Modification of Paclitaxel-Loaded Nanoparticles Based on Polydopamine with Ph Sensitive Property for Targeted Therapy in Hepatocellular Carcinoma

Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models

HPA Aptamer Functionalized Paclitaxel-Loaded PLGA Nanoparticles for Enhanced Anticancer Therapy Through Targeted Effects and Microenvironment Modulation.

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer.

A new core–shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma

Emerging Nanomedicines of Paclitaxel for Cancer Treatment

Enhanced in Vitro and in Vivo Therapeutic Efficacy of Codrug-Loaded Nanoparticles Against Liver Cancer

Molecular Pathways and Functional Analysis of Mirna Expression Associated with Paclitaxel-Induced Apoptosis in Hepatocellular Carcinoma Cells

Discovery of Coumarin As Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel

Emerging nanotaxanes for cancer therapy

48 Transferrin-modified Self-Assembled HSA (human Serum Albumin) Nanoparticles Enhance Drug Delivery to Tumors

Abstract #3667: A novel folate receptor-targeted nanoparticle minimizes drug resistance in a human cancer model

Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.

Nab-paclitaxel Promotes the Cancer-Immunity Cycle As a Potential Immunomodulator.